Event showcasing Sawai's proprietary technologies and the future of healthcare

The Sawai Group Innovation Meetup in March 2026 showcased the formulation technologies that the Group has cultivated over many years in the generic drug business, as well as the digital healthcare and medical devices that form a key focus of our new businesses. Hands-on exhibits and presentations allowed internal and external stakeholders to experience new possibilities for healthcare.



Mitsuo Sawai

Representative Director,
Chairman and President,
Group Chief Executive Officer and
Group Chief Operating Officer
Sawai Group Holdings Co., Ltd.

Presentation: AI applications
in the Research and Development Division

Takuro Nishimura

Pharmaceutical Development Department
Sawai Pharmaceutical


Event Overview

Date: Friday, March 13, 2026,
13:00-17:00
Invitees: Investors, analysts,
and members of the media
Attendees: 33

Date: Saturday, March 14, 2026,
10:30-15:45
Invitees: Employees and their families,
and executives
Number of visitors: 314

Sawai Group Technology

SAWAI HARMOTECH®



Proprietary formulation technologies supporting the Sawai Group's unique value and stable supply

SAWAI HARMOTECH® is Sawai Pharmaceutical's suite of formulation technologies to improve the ease of taking and using medications, developed through extensive analysis of feedback from patients and healthcare professionals. The platform comprises nine proprietary technologies, including orally disintegrating tablet and film coating technologies. These technologies improve the experience of taking medications while also enhancing convenience through better storability and portability. SAWAI HARMOTECH® addresses the needs of patients and healthcare providers by adding new value to pharmaceuticals and helping make medications easier to use.

Sawai Group's contribution to value and supply stability

The Sawai Group's formulation technologies are built on the knowledge and experience accumulated through research and the development of new products. Our researchers tackle new challenges every day by combining expertise in formulation technology, physicochemical analysis, pharmacokinetics, and intellectual property. As we develop and advance our proprietary technologies, SAWAI HARMOTECH® serves as our foundation for adding value to medications and ensuring a stable supply.

Toyohiro Sawada

Senior Executive Officer,
Group Chief Research &
Development Officer (Group CRO)
Sawai Group Holdings Co., Ltd.



Standout products featured at the Innovation Meetup

Supporting healthy lives and expanding treatment options

sawai

The launch of HAUDY* support app for treatment to reduce alcohol consumption

HAUDY is a prescription digital therapeutic designed to support treatment for alcohol dependence. The app, comprising a patient app and a physician app, is prescribed as a tool to help patients change their drinking habits and reduce alcohol consumption. Clinical trials have demonstrated its effectiveness, and HAUDY is covered by Japan's national health insurance system.

Wider adoption of HAUDY is expected to encourage more patients with alcohol dependence to start treatment.

* Product name: CureApp AUD Alcohol Reduction Treatment Support App



Relivion® device offering a new treatment option for migraine

Relivion® is a neuromodulation device that uses electrical stimulation to relieve pain from acute migraine attacks. New drug therapies for migraine continue to emerge, but side effects and other factors make medication unsuitable for many patients. Neuromodulation treatment, which regulates nerve function with electrical, magnetic, or other forms of stimulation, is already established in Europe and the United States as a non-pharmacological treatment option for migraine.

The Sawai Group aims to bring Relivion® to patients as Japan's first non-medication treatment option for migraine.



FrontAct



Takehiko Nomura
Representative Director, President and CEO

Accelerating value creation in digital healthcare as a member of the Sawai Group

FrontAct specializes in digital technologies that address healthcare challenges through biosignal sensing and algorithm-based analysis. We have developed and delivered innovative healthcare services spanning the continuum of care, from the pre-disease and prevention stages through long-term care.

Since joining the Sawai Group in 2025, FrontAct has been building on the Group's business platform and network while collaborating with Group companies to create greater value across both existing and new businesses.



MELTz® hand function rehabilitation device

The MELTz® Hand Rehabilitation System is a medical device that helps restore hand function in patients with hand paralysis, primarily following stroke. The system measures and analyzes the faint electrical signals (biosignals) generated by muscles when patients intend to move, animating a robotic exoskeleton to assist finger and hand movement.

More than 50 medical and rehabilitation facilities have adopted the system. The Sawai Group aims to make MELTz® a widely available treatment option for patients with hand paralysis.



MiMoRy® wrist-worn activity tracker for healthier living

MiMoRy® is a wrist-worn activity monitor equipped with five high-performance sensors. Worn during daily activities, the device automatically captures data on steps, resting heart rate, sleep score, conversational activity, skin temperature, calories burned, and ultraviolet exposure. MiMoRy® is a non-medical device designed to support daily self-care and help users maintain good health.

The device prioritizes essential functions to reduce charging frequency, making it easy for older adults to use. The Sawai Group provides MiMoRy® to companies, research institutions, and local governments.